At week @ , patients receiving brodalumab were randomly assigned again to receive a brodalumab maintenance dose of @ mg every @ weeks or @ mg every @ weeks , every @ weeks , or every @ weeks ; patients receiving ustekinumab continued to receive ustekinumab every @ weeks , and patients receiving placebo received @ mg of brodalumab every @ weeks .